Appointment of Nominated Adviser and Joint Broker, Clinigen Group plc, 2020-05-01
1 May 2020
Appointment of Nominated Adviser and Joint Broker
Clinigen Group plc (AIM: CLIN, “Clinigen” or the “Company”), the global pharmaceutical and services company, has appointed J.P.Morgan Cazenove as Nominated Adviser and Joint Broker with immediate effect. RBC Capital Markets will continue to act as the Company’s Joint Broker.
Clinigen Group plc
Tel: +44 (0) 1283 495 010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
J.P.Morgan Cazenove – Nominated Adviser & Joint Broker
Tel: +44 (0) 20 7742 4000
James Mitford / Hemant Kapoor
RBC Capital Markets – Joint Broker
Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage
Email: [email protected]
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com
Leave a Reply